The Latest in the Legal Battle for Psilocybin Access for Patients
This case marks another development in the years-long efforts to make psilocybin legally accessible for patients for therapeutic purposes.
On Friday, October 20th, the Ninth Circuit Court of Appeals heard Aggarwal v. United States Drug Enforcement Administration, which centered around the efforts of Sunil Aggarwal, MD to be able to provide psilocybin for terminally ill patients and patients with anxiety and depression (1,2). Dr. Aggarwal, a palliative care physician, is a co-founder of the Advanced Integrative Medical Science Institute (AIMS), which is “an outpatient clinic and research institute dedicated to advancing integrative medical care, research, and education within oncology, psychiatry, neurology, rehabilitation, pain, and palliative care,” (2). For the past few years, he and his team have been taking legal actions to make psilocybin widely and legally accessible, including filing a petition to reschedule psilocybin, which was denied by the Drug Enforcement Administration (DEA) in September 2022 (1,2).
“The [current] case seeks federal court review of the DEA’s denial of a petition to reschedule psilocybin (commonly called magic mushrooms) from a highly restricted Schedule I drug to a less restricted Schedule II so that it can be accessed by physicians and other providers to help those with terminal and other life-threatening conditions,” stated a press release on the AIMS website (2). “This case focuses on DEA’s long history of applying an inaccurate test to rescheduling petitions. The outcome of this case could have implications for other emerging and promising therapies.”
Other statements presented by the lawyers representing Dr. Aggarwal included arguments that the DEA did not fully consider the evidence that they had presented in their petition supporting psilocybin as having current accepted medical use, and the argument that the petition should be referred to the Department of Health and Human Services (HHS) (1).
Watch the full case here (starting at 1 hour and 36 minutes into the clip).
For in-depth insight into Dr. Aggarwal’s accomplishments and goals, read The Path to Legalized, Accessible Psilocybin Therapy from our psychedelics issue,Psychedelics: New Frontiers in Alternative Medicine.
References
- Adlin, B. Federal Court hears case challenging DEA decision to deny psilocybin rescheduling petition without consulting health officials https://www.marijuanamoment.net/federal-court-hears-case-challenging-dea-decision-to-deny-psilocybin-rescheduling-petition-without-consulting-health-officials/ (accessed Oct 23, 2023).
- Media Advisory for federal appeals court - psilocybin case hearing https://www.aimsinstitute.net/media-advisory-for-federal-appeals-court-psilocybin-case-hearing/ (accessed Oct 23, 2023).
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
